|NewLink Genetics Corporation|
2503 South Loop Drive
United States - Map
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase pathway and the tryptophan-(2.3)-dioxygenase pathway. The companys lead product candidate, HyperAcute Pancreas immunotherapy, is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for treating advanced non-small cell lung cancer; and HyperAcute Melanoma immunotherapy for treating advanced melanoma, as well as HyperAcute immunotherapies for renal, prostate, and breast cancers. In addition, the company is developing IDO pathway inhibitors comprising indoximod and NLG919 for metastatic breast cancer and metastatic prostate cancer; NLG2101 for patients with metastatic breast cancer; NLG2102 for treating refractory malignant brain tumors; NLG2103 for patients with advanced melanoma; and NLG2014 for patients with metastatic pancreatic cancer. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
|NewLink Genetics Corporation’s ISS Governance QuickScore as of Oct 1, 2015 is 9. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Charles J. Link Jr., M.D.,
Founder, Chairman, Chief Exec. Officer and Chief Scientific Officer
|Mr. Nicholas N. Vahanian M.D.,
Pres, Chief Operations Officer and Chief Medical Officer
|Mr. John B. Henneman III ,
Chief Financial Officer, Exec. VP and Sec.
|Mr. Brian Wiley ,
VP of Bus. Devel.
|Mr. Carl W. Langren ,
Principal Accounting Officer and VP of Fin.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|